Cardiac Myosin Activation in Heart Failure Management
Summary
Heart failure with reduced ejection fraction (HFrEF) is characterised by impaired myocardial contractility leading to inadequate cardiac output and progressive clinical decline. Traditional pharmacological strategies have focused on neurohormonal modulation to counteract maladaptive pathways, yet residual mortality and morbidity remain substantial. Cardiac myosin activation represents a novel therapeutic paradigm that directly enhances the contractile machinery of cardiomyocytes without elevating intracellular calcium concentrations. By stabilising the interaction between myosin heads and actin filaments, selective activators prolong systolic ejection time and improve stroke volume, thereby augmenting systolic function while minimising adverse energetic demands. Early-phase and pivotal trials of a first-in-class myosin activator have demonstrated modest but significant reductions in events related to heart failure worsening and cardiovascular death, particularly in patients with elevated biomarkers of haemodynamic stress. The approach holds promise as an adjunctive measure to standard treatment, potentially addressing the residual contractile deficit that underpins disease progression. Ongoing investigations aim to refine patient selection, optimise dosing, and elucidate long-term effects on cardiac remodelling and clinical outcomes.
Research from Nature Portfolio
No recent Nature Portfolio content available.
Cardiac Myosin Activation in Heart Failure Management publication trend
The graph below shows the total number of articles in cardiac myosin activation in heart failure management across all publications each year (not limited to Nature Index journals).
Technical terms
Cardiac myosin: The motor protein in heart muscle cells responsible for force generation during contraction.
Myosin activator: A class of agent that enhances cardiac contractility by increasing the efficiency of myosin–actin interactions.
Heart failure with reduced ejection fraction (HFrEF): A subtype of heart failure in which the left ventricle cannot contract effectively, lowering the fraction of blood ejected with each beat.
Ejection fraction: The percentage of ventricular blood volume expelled during systole, a key measure of pump function.
N-terminal pro-B-type natriuretic peptide (NT-proBNP): A circulating biomarker released in response to ventricular wall stress, used to gauge severity and prognosis in heart failure.
Systolic function: The ability of the heart to contract and eject blood, essential for maintaining adequate circulation.
References
- Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B‐type natriuretic peptide level: insights from the GALACTIC‐HF trial. European Journal of Heart Failure (2023).
- The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF. Journal of Cardiac Failure (2023).
- Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium. International Journal of Molecular Sciences (2024).
- Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management. Cureus (2021).
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.